Why Liquidia Stock Rocked the Market Today

Biotech Liquidia (NASDAQ: LQDA) had good news to report about its latest commercialized product as the trading week came to a close. On an update about that product, Yutrepia, investors snapped up the company's shares to boost them to a nearly 13% gain on Friday. Before market open, Liquidia published preliminary sales results for Yutrepia for 2025. The drug, which is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension with interstitial lung disease (PH-ILD), was approved by the U.S. Food and Drug Administration (FDA) for both conditions last May. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool